Mitesh J. Borad, MD, on Hepatobiliary Cancers: Management Updates
NCCN 2023 Annual Conference
Mitesh J. Borad, MD, of the Mayo Clinic Comprehensive Cancer Center, discusses the expanding number of options in immunotherapies for patients with advanced hepatobiliary cancers, applying targeted treatments to this disease, and the importance of genomic profiling in patients with biliary tract cancers.
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
It's been an exciting few years in the management of patients with hepatobiliary cancers. From this perspective, I had the opportunity to present on a number of themes that are relevant to day-to-day practice for these patients. Starting off, we would have the management of patients with advanced hepatocellular cancer who have advanced disease, recurrent disease, or metastatic disease. From this perspective, we have a number of different treatment options now with serafenib and lenvatinib as the tyrosine kinase inhibitor options, atezolizumab and bevacizumab as a doublet that has an antiangiogenic and a checkpoint inhibitor, and from the Himalaya study now, durvalumab and tremelimumab, which constitutes a dual checkpoint-based approach.
In terms of management of advanced biliary tract cancers in the first line setting, again, we have a very exciting development in the form of TOPAZ-1, where now we see that the addition of durvalumab to gemcitabine and cisplatin, standard therapy leads to survival improvements. Biliary tract cancers, as we know through the application of next generation sequencing, have exhibited a large array of targets in terms of things that we could pursue with available drugs and those in development. From this perspective, we have a number of agents that are already FDA-approved.
These include the fibroblast growth factor receptor inhibitors, pemigatinib, futibatinib, and infigratinib, which was unfortunately recently withdrawn, but was FDA-approved as the first agent in this space, along with itacitinib, which targets IDH-1 mutations. So, there's an array of drugs specifically approved for advanced biliary tract cancers with these alterations, and there's a very robust pipeline of agents being developed to other targets. This also highlights a very important facet for these cancers, that genomic profiling should be very much a standard approach, whether it's through tissue-based assessments or liquid biopsy assessments, or both preferably, and opens up a new arena in how we think about these cancers beyond cytotoxic agents.
All in all, the last few years have been a tour de force with advances, which will hopefully translate to more and more improvements that we can see in the clinic in terms of survival benefits, quality of life improvements, and hope for patients.
Natalie Moryl, MD, of Memorial Sloan Kettering Cancer Center, discusses severe cancer pain, a medical emergency that should be addressed with immediate intervention. The treatment plan, Dr. Moryl says, should include making a pain diagnosis; addressing reversible causes of pain such as spinal cord compression, fracture, or obstruction; selecting, titrating, and rotating opioids and co-analgesics; and routine screening for risks of opioid use disorder and mental health comorbidities.
Midhun Malla, MD, of the West Virginia University Cancer Institute, discusses the molecular landscape of metastatic colorectal cancer and the development and approvals of targeted treatments. Dr. Malla also details the range of HER2-targeted therapeutic options and the approval of trastuzumab and tucatinib for HER2-amplified disease in the second-line setting or after. In addition, he discusses emerging therapies in refractory metastatic colorectal cancers followed by circulating tumor DNA–guided management of oligometastatic colorectal cancers using immune checkpoint inhibitors.
Deborah M. Stephens, DO, of the Huntsman Cancer Institute at the University of Utah, discusses NCCN’s updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr. Stephens details the key factors in selecting front-line and subsequent therapies, including IGHV status, del(17p)/TP53 mutation status, age, comorbidities, and resistance mutations.
Jordan McPherson, PharmD, MS, BCOP, of the Huntsman Cancer Institute at the University of Utah, summarizes a case-based panel discussion on best practices in caring for patients with immune-related adverse events. He focuses on pneumonitis, which can occur with immune checkpoint inhibitor therapy, detailing factors such as comorbidities, infectious etiology, and disease progression; the need to consider myositis and myasthenia gravis in patients who develop immune-related myocarditis; and oral toxicities including mucositis and sicca syndrome.
Mandi L. Pratt-Chapman, PhD, of the George Washington University Cancer Center, discusses the specific health-care needs for cancer screening, treatment, and survivorship among members of the LGBTQI+ community. Because clinical practices and research studies do not routinely collect sexual orientation and gender identity data, there is insufficient evidence to guide clinical care decision-making, Dr. Pratt-Chapman says.